ストックスクリーナーアプリを入手
5.7364
5.11%
-0.3036
前日終値:
$6.04
開ける：
$6.02
24時間の取引高:
5.37M
Relative Volume:
1.02
時価総額：
$1.69B
収益：
$43.88M
当期純損益:
$-328.07M
株価収益率:
-4.1568
EPS:
-1.38
ネットキャッシュフロー:
$-300.33M
1週間 パフォーマンス:
-17.06%
1か月 パフォーマンス:
-15.21%
6か月 パフォーマンス:
-39.73%
1年 パフォーマンス:
-12.36%
1日の値動き範囲:
$5.62
$6.03
1週間の範囲:
$5.62
$6.92
52週間の値動き範囲:
$5.62
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| RXRX | 5.735 | 1.69B | 43.88M | -328.07M | -300.33M | -1.38 |
| VRTX | 448.48 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.77 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.98 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine - Genetic Engineering & Biotechnology News
Cathie Wood's ARK makes major plays in Recursion, Twist Bioscience stock - Investing.com
RecursionNo News Isn't Good News When It Comes To Vanilla Pipeline (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals’ Strategic Acquisition and Leadership Changes - TipRanks
Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery - Wahanariau
Recursion and Exscientia, two leaders in the AI drug - GlobeNewswire
Recursion Completes Exscientia Merger, Creates AI Drug Discovery Powerhouse with $20B+ Pipeline | RXRX Stock News - StockTitan
Recursion Pharmaceuticals stock hits 52-week low at $5.88 - Investing.com India
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 1-Year LowHere's What Happened - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $5.88 By Investing.com - Investing.com Canada
Recursion Pharmaceuticals CEO sells $301,800 in stock - Investing.com India
Recursion Pharmaceuticals director Blake Borgeson sells $87,457 in stock - Investing.com Canada
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% Following Insider Selling - MarketBeat
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Trims Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals CFO Michael Secora sells $229,504 in stock - Investing.com
Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Recursion and Exscientia Shareholders Approve the Proposed Combination - The Manila Times
Recursion & Exscientia Merger Approved: AI Drug Discovery Giants Set to Unite | RXRX Stock News - StockTitan
Recursion releases OpenPhenom-S/16 for microscopy data By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition in Recursion Pharmaceuticals Inc - GuruFocus.com
Recursion releases OpenPhenom-S/16 for microscopy data - Investing.com
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden - GlobeNewswire
Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud?s Model Garden - Marketscreener.com
Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for RXRX Earnings - MarketBeat
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - Simply Wall St
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - Yahoo Finance
ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk - Simply Wall St
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals - Benzinga
Recursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones - TipRanks
Recursion Pharmaceuticals: Q3 Earnings Snapshot - Barchart
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Recursion Pharmaceuticals Inc Cl A (RXRX-Q) QuotePress Release - The Globe and Mail
Is Recursion Pharmaceuticals a Millionaire-Maker Stock? - AOL
Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Pre - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition in Recursion Pharmace - GuruFocus.com
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - MSN
(RXRX) Technical Pivots with Risk Controls - Stock Traders Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker? - AOL
Mirae Asset Global Investments Co. Ltd. Purchases 80,664 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals director Blake Borgeson sells $76,926 in stock - Investing.com India
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
Recursion Pharmaceuticals Inc (RXRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
Nov 14 '24 |
Sale |
7.35 |
20,000 |
147,000 |
762,656 |
| Borgeson Blake | Director |
Nov 12 '24 |
Sale |
7.64 |
11,447 |
87,457 |
7,066,113 |
| Secora Michael | Chief Financial Officer |
Nov 12 '24 |
Option Exercise |
2.22 |
39,375 |
87,413 |
1,490,256 |
| Secora Michael | Chief Financial Officer |
Nov 13 '24 |
Option Exercise |
2.22 |
39,375 |
87,413 |
1,514,631 |
| Secora Michael | Chief Financial Officer |
Nov 13 '24 |
Sale |
7.66 |
15,000 |
114,876 |
1,499,631 |
| Secora Michael | Chief Financial Officer |
Nov 12 '24 |
Sale |
7.64 |
15,000 |
114,628 |
1,475,256 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):